Novo Nordisk launches once-weekly insulin Awiqli in US market
Danish pharmaceutical company ‘Novo Nordisk’ has launched a once-weekly insulin injection in the US market. EPA/MARTIN DIVISEK/Yonhap News…
Novo Nordisk Escalates Legal Battle Against Eli Lilly
Novo Nordisk is taking its legal dispute with Eli Lilly to the next level by seeking a preliminary…
Novo Nordisk sues Eli Lilly over alleged false advertising for weight loss drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly, accusing the latter of false advertising regarding weight-loss medications.…
Novo Nordisk sues Eli Lilly over alleged false advertising for weight loss drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly, accusing the latter of false advertising regarding weight-loss medications.…
Novo Nordisk sues Eli Lilly over alleged false advertising for weight loss drugs – WSB-TV Channel 2
Novo Nordisk filed a lawsuit against rival Eli Lilly, accusing the latter of false advertising regarding weight-loss medications.…
Novo Nordisk launches world’s first once-weekly basal insulin in India at Rs 3.71 per unit
Novo Nordisk launches world’s first once-weekly basal insulin in India at Rs 3.71 per unit July 09, 2026…
European Lithium’s Greenland Merger Tightens as Offtake and Cash Injection Clear Path to Productio
European Lithium jumps 7% after binding takeover by Critical Metals Corp and 15-year offtake deal for Tanbreez rare…
Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Novo Nordisk’s Wegovy® HD available now nationwide
Wegovy® HD available through 70,000+ US pharmacies, NovoCare® Pharmacy, select telehealth providers, and more Wegovy® HD further expands the offerings…
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment*…
FDA approves Novo Nordisk’s new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment*…